U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07446998) titled 'Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss' on Feb. 25.
Brief Summary: The primary objective of this study is to assess the effect of enobosarm on total body weight
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Obesity & Overweight
Mobility Disability
HOMA-IR
Intervention:
DRUG: Enobosarm
Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves ins...